1. FRI0214 Long-term efficacy and safety of sirukumab in patients with active rheumatoid arthritis despite anti-tumor necrosis factor therapy: results of the randomized, phase 3 sirround-t study. (15th June 2017) Authors: Tanaka, Y; Aletaha, D; Agarwal, P; Kurrasch, R; Tak, PP; Popik, S Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 563 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. FRI0251 SIRUKUMAB, an ANTI-IL-6 cytokine monoclonal antibody, leads to improvements in work productivity and general health status in patients with active rheumatoid arthritis refractory to ANTI-TNF therapy: results from the phase 3 SIRROUND-T study. (15th June 2017) Authors: Tanaka, Y; Aletaha, D; Peterson, S; Ganguly, R; Kurrasch, R; Popik, S; Agarwal, P; Li, N Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 580 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. FRI0252 Summary of neutropenia in patients with rheumatoid arthritis treated with sirukumab in the sirround phase 3 clinical trials. (15th June 2017) Authors: Takeuchi, T; Tanaka, Y; Schiff, M; Harigai, M; Brown, K; Rao, R; Fei, K; Popik, S; Yoshizawa, K; Wang, Q; Hsu, B Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 581 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗